As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

AAM, the Biosimilars Council and NACDS commended the FDA for its announcement to make it faster and less costly to develop biosimilar medicines. The Association for Accessible Medicines and its ...

CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...

Evernorth Health Services, a subsidiary of Cigna, plans to have a Stelara biosimilar available for $0 out-of-pocket cost for eligible patients of its specialty pharmacy, Accredo, beginning in early ...

Join our 2024 Mid Year Pharmacy Benefits Update webinar for a comprehensive analysis of the current pharmacy landscape. This informative session will delve into key trends, including the evolving ...

Leslie Fish, PharmD, senior vice president of pharmacy at IDP Analytics, LLC, reflects on the future of biosimilars and the impact they will have on managed care pharmacy settings to improve patient ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Please provide your email address to receive an email when new articles are posted on . CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national ...

There are multiple levers that need to be pulled to allow biosimilars to come to market more broadly in the US, explained Fran Gregory, PharmD, MBA, vice president of emerging therapies, Cardinal ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As members of Congress begin negotiating the continuing resolution set for ...

The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...